HOME >> BIOLOGY >> NEWS
First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox

ST. LOUIS - Not everybody can safely be vaccinated against smallpox using the current FDA-approved vaccine. Scientists hope another study vaccine, now undergoing its first testing in the United States at Saint Louis University, will give a choice to people who can't be given the current vaccine, known as Dryvax.

"There are limits to the current vaccine," said Sharon Frey, M.D., from Saint Louis University's Center for Vaccine Development. "You can't give Dryvax to people with certain skin conditions, such as eczema, or to people who are immunosuppressed. So, for example, if you are HIV-positive or undergoing chemotherapy for cancer, you shouldn't receive the currently licensed vaccine."

Dr. Frey said this study vaccine, known as MVA-BN and provided through Bavarian Nordic, is different than other vaccines that are now available. Like the current vaccines, the study vaccine is a live-virus vaccine made from vaccinia virus, but this study vaccine contains a much more "attenuated," or weakened, form of the virus.

"The thinking is that the study vaccine is much more attenuated, therefore the side effects should be less. So the hope is you may be able to give it to someone who is immunosuppressed. These are some of the questions we'll be studying as we start testing this investigational drug. If our studies prove successful, we hope this vaccine can be given to people for whom Dryvax is contraindicated."

MVA-BN also is administered in a different way. Dryvax is administered using a method called scarification, in which the skin is poked with a bifurcated needle just enough to puncture the skin. The study vaccine being tested will be administered intramuscularly, as a flu shot is given, or subcutaneously between the skin and muscle, as an insulin shot is given.

The study will enroll 90 adult volunteers into six different groups. MVA-BN will be given in three different dose strengths alone or in combination with Dryvax. The study i
'"/>

Contact: Joe Muehlenkamp
muehlenk@slu.edu
314-977-8015
Saint Louis University
10-May-2004


Page: 1 2

Related biology news :

1. First glimpse of DNA binding to viral enzyme
2. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
3. 2nd media alert First Scientific Conference on Childhood Leukaemia
4. First International Scientific Conference on Childhood Leukaemia
5. First ever standards linking climate change, biodiversity and poverty seek global peer review
6. First genetic comparison of purebred domestic dogs produces surprises
7. First target for childhood malaria vaccine
8. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
9. First flavors form a lasting impression
10. STN International launches Derwent World Patents Index First View
11. First DFG research conference in the USA

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/17/2019)... ... July 16, 2019 , ... At nearly eleven years ... legs. According to his owner, in the last year or so, he was ... His veterinarian, Dr. Cindy Echevarria of VCA University Animal Hospital in ...
(Date:7/11/2019)... ... July 11, 2019 , ... ... first on-site Legionella DNA test, today announced a partnership with LiquiTech, a ... , Through this strategic partnership, LiquiTech will integrate Spartan’s innovative environmental DNA ...
(Date:7/9/2019)... ... July 09, 2019 , ... Murrieta Genomics, ... its incubator program. The founder and CEO of Tx Genetic, Helen Harrison, has ... those suffering from epithelial connective tissue disorders. , “We are pleased and excited ...
Breaking Biology News(10 mins):
(Date:7/11/2019)... ... July 11, 2019 , ... At the most recent ... therapies to eight military Veterans under the R3 Heroes Program. The Veterans included individuals ... R3 Heroes Program allow anyone to nominate a military Veteran, teacher or first responder ...
(Date:6/26/2019)... ... June 26, 2019 , ... Alice Branton today released research results from ... of Magnesium Gluconate, which can prove to be beneficial for treating Hypomagnesemia. , The ... peak, change in crystallite size , Over 142% increase in particle size ...
(Date:6/11/2019)... , ... June 10, 2019 , ... ... its distribution network with the appointment of Biofeedback Tech Ltd as ... systems are an essential part of many therapeutic treatments and clinical assessment protocols ...
(Date:6/11/2019)... ... June 11, 2019 , ... Veterinary Regenerative Medicine ... (PSC) , has announced that their GMP facility for cell production is now ... manufacturing. This is an important milestone for VetStem as it expands into ...
Breaking Biology Technology:
Cached News: